Aurobindo gears up for multiple Covid-19 vaccines, ties up with CSIR

Aurobindo Pharma
Hyderabad-based Aurobindo Pharmaceuticals is gearing up to develop and manufacture multiple Covid-19 vaccine candidates. It has taken help from the Department of Biotechnology (DBT) for its own vaccine candidate and has also tied up with the Council of Scientific and Industrial Research (CSIR) for the multiple vaccine candidates the latter is developing. 

Biotechnology Industry Research Assistance Council (BIRAC), a not-for-profit enterprise set up by the DBT, has facilitated the establishment of the r-VSV vaccine manufacturing platform for Aurobindo. The company is developing a Sars-Cov-2 vaccine through its wholly-owned US-based subsidiary Auro Vaccines based on its proprietry replication-competent attenuated (weakened) recombinant vesicular stomatitis (VSV, VesiculoVax) vaccine delivery platform, the company said. To put in simple words, the vaccine technology uses a VSV or vesicular stomatitis virus that has been genetically engineered. Similar technology was used to develop Ebola vaccine. 

Aurobindo said that it setting up a manufacturing plant for viral vaccines. Auro Vaccines has a 300-million-dose-per-annum plant, informed a source. Currently, no other vaccine is getting manufactured at the site and thus the entire capacity can be dedicated to Covid-19 vaccines if need be. 

Meanwhile, the company has also tied up with the CSIR to develop vaccines. CSIR-Centre for Cellular and Molecular Biology (CCMB) and Aurobindo Pharma, Aurobindo will partner with CSIR for development of several novel Covid-19 vaccines. Three CSIR labs-- CCMB Hyderabad, Institute of Medical Technology (IMTECH), Chandigarh and Indian Institute of Chemical Biology (IICB), Kolkata--are developing vaccine candidates using different technology platforms. Aurobindo will undertake clinical development and commercialisation of the vaccines. 

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel